Addressing sequential and concurrent treatment regimens in a small n sequential, multiple assignment, randomized...

Area of Science:

• Pediatric infectious diseases
• Clinical trial methodology
• Biostatistics

Background:

• Multisystem Inflammatory Syndrome in children (MIS-C) is a rare complication of COVID-19, first identified in 2020.
• The MISTIC study used a small n, Sequential, Multiple Assignment, Randomized Trial (snSMART) to evaluate treatments like steroids, infliximab, and anakinra.
• Concurrent treatment administration was necessary due to disease urgency, posing analytical challenges for the standard snSMART design.

Purpose of the Study:

• To propose a modified Bayesian joint stage model for analyzing concurrent versus sequential treatments in MIS-C clinical trials.
• To address the limitations of the standard snSMART design when treatments are not strictly sequential.
• To improve the accuracy and efficiency of estimating treatment response rates in complex trial designs.

Main Methods:

• Development of a modified Bayesian joint stage model capable of distinguishing concurrent and sequential treatment effects.
• Application of the model to analyze data from the MISTIC snSMART study.
• Conducting a simulation study to compare the modified model with the standard snSMART Bayesian joint stage model.

Main Results:

• The modified Bayesian model demonstrated improved accuracy and efficiency in estimating first-stage and combined first- and second-stage treatment responses.
• Simulations showed reduced bias and improved root mean squared error (rMSE) for the modified model, particularly in large sample settings.
• The proposed model effectively analyzes concurrent and sequential treatment administration within a unified framework.

Conclusions:

• The modified Bayesian joint stage model offers a pragmatic and effective approach for analyzing clinical trials with concurrent and sequential treatment designs, such as in MIS-C studies.
• This methodological advancement enhances the ability to evaluate complex treatment strategies in rare and urgent pediatric conditions.
• The findings support the use of this modified model for more precise and efficient clinical trial data analysis.